Rheumatology and oncology: An updated review of rheumatic manifestations of malignancy and anti-neoplastic therapy

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 2, 2012, Pages 109-114

  Alias, Abie ^a   Rodriguez, Ernesto J ^a   Bateman, Helen ^a   Sterrett, Ashley ^a   Valeriano Marcet, Joanne ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AUTOANTIBODY; BCG VACCINE; BLEOMYCIN; CISPLATIN; INTERLEUKIN 2; PHOSPHOLIPID ANTIBODY; VINBLASTINE;

ANDROGEN THERAPY; ANKYLOSING SPONDYLITIS; ARTHRITIS; CANCER THERAPY; CARCINOMATOUS POLYARTHRITIS; DISEASE ASSOCIATION; EDEMA; ERYTHROMELALGIA; FASCIITIS; GERM CELL TUMOR; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; INFLAMMATION; KIDNEY CARCINOMA; LYMPHOMA; MELANOMA; MYOPATHY; MYOSITIS; NECROTIZING MYOSITIS; PALMAR FASCIITIS; PARANEOPLASTIC SYNDROME; POLYARTHRITIS; PSORIATIC ARTHRITIS; PULMONARY VASCULITIS; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; SCLERODERMA; SERODIAGNOSIS; SYNOVITIS;

ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 84864987985     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Andras C, Csiki Z, Ponyi A, et al. Paraneoplastic rheumatic syndromes. Rheumatol Int. 2006 Mar;26:376-82.
2. Fam AG. Paraneoplastic rheumatic syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000 Sep;14:515-33.
3. Silveira LH, Martinez-Lavin M, Pineda C, et al. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol. 2000 Jan-Feb;18:57-62.
4. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010 Aug;40:89-94.
5. Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004 Jul;29:654-60.
6. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001 Jan 13;357:96-100.
7. Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009 Mar;88:91-7.
8. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol. 2008 Oct;14:285-8.
9. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007 Oct;66:1345-9.
10. Hengstman GJ, Vree Egberts WT, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006 Feb;65:242-5.
11. Madan V, Chinoy H, Griffiths CE, et al. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol. 2009 Jul;34:561-5.
12. Selva-O'Callaghan A, Grau JM, Gamez-Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/ polymyositis. Am J Med. 2010 Jun;123:558-62.
13. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007 Dec 15;57:1473-80.
14. Kermani TA, Schafer VS, Crowson CS, et al. Cancer preceding giant cell arteritis: a case-control study. Arthritis Rheum. 2010 Jun;62:1763-9.
15. Myklebust G, Wilsgaard T, Jacobsen BK, et al. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002 Oct;29:2143-7.
16. Liozon E, Loustaud V, Fauchais AL, et al. Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol. 2006 Aug;33:1606-14.
17. Naschitz JE, Slobodin G, Yeshurun D, et al. Atypical polymyalgia rheumatica as a presentation of metastatic cancer. Arch Intern Med. 1997 Nov 10;157:2381.
18. Buggiani G, Krysenka A, Grazzini M, et al. Paraneoplastic vasculitis and paraneoplastic vascular syndromes. Dermatol Ther. 2010 Nov;23:597-605.
19. Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev. 2010 Feb;9:200-2.
20. Miesbach W, Asherson RA, Cervera R, et al. The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome. Clin Rheumatol. 2007 Dec;26:2109-14.
21. Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.
22. Warner E, Keshavjee al N, Shupak R, et al. Rheumatic symptoms following adjuvant therapy for breast cancer. Am J Clin Oncol. 1997 Jun;20:322-6.
23. Amft N, D'Cruz D. Postchemotherapy connective tissue diseases--more than just rheumatism? Lupus. 1996 Aug;5:255-6.
24. Raderer M, Scheithauer W. Postchemotherapy rheumatism following adjuvant therapy for ovarian cancer. Scand J Rheumatol. 1994;23:291-2.
25. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70.
26. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007 Sep 1;25:3877-83.
27. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.
28. Moxley G. Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer. 2010 Apr;10:144-7.
29. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005 Sep;52:2594-8.
30. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22.
31. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.
32. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Nov 1;21:4042-57.
33. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997 Feb;157:439-44.
34. Bannwarth B. Drug-induced rheumatic disorders. Rev Rhum Engl Ed. 1996 Nov;63:639-47.
35. Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8.
36. Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8.
37. Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981 Sep;95:288-92.
38. Hansen SW, Olsen N. Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol. 1989 Jul;7:940-2.
39. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.
40. Adelman H, Carter JD, Ricca L, Sterrett A. Case 26. In: Valeriano J, Bateman H, (eds): Visual Diagnosis Self-tests on Rheumatology (3rd ed). Boca Raton, FL: Merit Publishing, 2009, pp. 125-126.
41. Tsukadaira A, Okubo Y, Takashi S, et al. Repeated arthralgia associated with granulocyte colony stimulating factor administration. Ann Rheum Dis. 2002 Sep;61:849-50.
42. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000 Jul;43:1431-42.
43. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44:1016-20.
44. Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995 Oct 1;76:1219-23.
45. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003 Jan;42:34-9.